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The pathogenesis of Systemic Sclerosis (SSc) is complex and despite numerous studies that have examined several aspects of its intricate picture, the exact mechanisms involved are not well understood [1] [2] [3] [4] . However, it is apparent that the most severe clinical and pathologic manifestations of the disease are the result of a fibrotic process characterized by the excessive and often progressive deposition of collagen and other connective tissue macromolecules in skin and numerous internal organs. Tissue fibrosis in SSc is the result of an upregulated expression of genes encoding collagen and other extracellular matrix proteins in affected organs. This is the most important difference that distinguishes normal fibroblasts that promote normal wound healing from SSc fibroblasts which display exaggerated and uncontrolled collagen and extracellular matrix (ECM) production resulting in pathologic organ fibrosis [5] [6] [7] [8] .
The excessive collagen deposition in SSc is due to overproduction of this protein by an expanded population of activated fibroblasts. Fibroblasts cultured in vitro from affected SSc skin show characteristic features distinct from those of normal fibroblasts. SSc fibroblasts appear to be very active in protein synthesis as demonstrated by the presence of distended and enlarged rough endoplasmic reticulum, abundant cytoplasm, and numerous membrane-bound vesicles containing proteinaceous amorphous material that most likely represent the exportation of newly synthesized collagen and other ECM macromolecules into the extracellular space. The exaggerated production of collagen and ECM proteins by SSc fibroblasts is maintained for serial passages in vitro, suggesting that fundamental alterations in the regulation of collagen gene expression have occurred in these cells [9, 10] .
A hallmark of the activation of fibroblasts is their conversion into myofibroblasts, a process in which cells acquire the expression of smooth muscle actin and develop contractile and convertdoc.input.557475.l9K2M 9:32: 05 PM 4 migratory properties [11] . In addition to their motile and contractile phenotype, myofibroblasts display highly increased biosynthetic activity for collagen and other ECM proteins. The transition into myofibroblasts involves a unique process of phenotypic transdifferentiation by which quiescent fibroblasts, epithelial cells or endothelial cells/pericytes acquire myofibroblast characteristics [12] [13] [14] .
The origin of the overproducer fibroblasts in SSc has not been completely elucidated and it is likely that several different pathways lead to the tissue expansion and accumulation of these cells [15] . At least three distinct mechanisms of fibroblast expansion occurring in fibrotic diseases have been identified. These include: (1) the activation of resident fibroblasts and the selection of matrix overproducer and apoptosis resistant cells [16, 17] through the effects of cytokines and growth factors released from inflammatory cells infiltrating the affected tissue, (2) the recruitment of circulating fibrocytes, a unique population of bone marrow derived mesenchymal cell precursors characterized by the presence of both mesenchymal cell and bone marrow origin markers [18] [19] [20] and (3) the transdifferentiation into myofibroblasts of either epithelial cells or vascular cells such as pericytes or endothelial cells, in epithelial to mesenchymal (EMT) or endothelial to mesenchymal transitions (EndoMT), respectively [12] [13] [14] [21] [22] [23] [24] .
Growth Factors
The mechanisms involved in the initiation and progression of the remarkable fibrotic process in SSc remain largely unknown [1] [2] [3] [4] . However, extensive recent studies have indicated that a variety of polypeptide growth factors play a crucial role in this process. In the following sections the experimental evidence supporting the participation of various growth factors in the convertdoc.input.557475.l9K2M 9:32:05 PM 5 pathogenesis of the fibrotic process in SSc and the molecular mechanisms involved will be reviewed.
Transforming growth factor beta (TGF-β). TGF-β is a pleotropic growth factor that plays crucial roles during embryogenesis, development of the immune system, malignant cell transformation, vascular morphogenesis, inflammatory response, and wound healing, among many others [25] [26] [27] . There are three isoforms of TGF-β which in addition to their primary structure differ in their cellular origin, the kinetics of their expression, and their overall effects, which are often organ specific and context-dependent. TGF-β1 is the most abundant isoform and is most frequently implicated in the pathogenesis of various fibrotic processes including those associated with SSc. TGF-β1 is produced by a large variety of cells, including fibroblasts and macrophages, and most cells in the body have receptors for this isoform. TGF-β is initially produced in a latent form in which the polypeptide is bound to a latency-associated peptide (LAP) and is carried to the extracellular compartment as a large complex with a carrier protein, latent TGF-β binding protein (LTBP). LTBP shuttles latent TGF-β to a storage compartment comprised of ECM proteins such as elastin fibrils and fibronectin-rich pericellular matrices [28] [29] . Release of active TGF-β from the ECM storage sites requires either proteolytic cleavage, which can be accomplished by numerous proteases including plasmin and certain matrix metalloproteinases, or by conformational changes induced by interactions with thrombospondin or certain integrins such as αvβ6 [30, 31] .
Canonical pathway of TGF-β signaling. Once activated, bioactive TGF-β in a dimeric form binds to one of several transmembrane kinase receptors (TβR) and initiates a complex series of intracellular reactions that transduce the signal from the cell surface to the nucleus and eventually to the transcriptional regulatory elements of numerous TGF-β-responsive genes. The signaling events involve numerous intracellular molecules and pathways as illustrated in Fig. (1) .
The classic pathway of TGF-β signal transduction involves the Smad family of intracellular proteins [32] [33] [34] [35] [36] and is initiated by binding of dimeric TGF-β to the constitutively active serine/threonine TβRII which recruits TβRI and then transphosphorylates it on three to five serine and threonine residues in a short (30 amino acid) regulatory sequence known as the GS region. TβRI is a member of a family of at least seven proteins known as activin receptor like kinases (ALK). In fibroblastic cells the TβRI is ALK-5 whereas in endothelial cells it is ALK-1 although signaling through ALK-1 has also been observed in fibroblasts (see Fig (1) ). The phosphorylated TβRI receptor transduces the signal to the nucleus through the Smad family of proteins. Smad2 or Smad3, two of the five receptor activated Smads (RSmads) then associate with another protein, SARA, and become phosphorylated by the activated TβRI.
Phosphorylation allows these proteins to form a complex with the co-Smad, Smad4, which is a cytoplasmic shuttle protein involved in the translocation of the Smad complex across the nuclear membrane into the nucleus. Once in the nucleus, Smad3/Smad4 complexes act as transcription factors by binding to specific DNA binding sites in the promoter regions of target genes and thereby activating their expression [37] . In contrast, Smad2/Smad4 complexes do not appear to directly bind to DNA promoter sites but instead exert their effect through their interactions with other transcription factors or co-activator proteins. In addition to the ALK-5 initiated signaling, it has been shown that in dermal fibroblasts important fibrogenic gene programs can also be induced by ALK-1-mediated activation of Smad1 [38] .
Fine tuning of TGF-β activity is achieved through a balance of positive and negative effector molecules [39] . Of critical importance is the inhibitory Smad, Smad7, which inhibits TGF-β signaling by binding to the type I receptor and thereby preventing recruitment and 7 phosphorylation of RSmads [40, 41] . Smad7 also facilitates TβRI ubiquitination by the Smurf proteins by targeting the receptor for degradation, which leads to inhibition of RSmad activation [42] . Other mechanisms of fine regulation include dephosphorylation of Smads through specific phosphatases as well as regulation of Smad nucleocytoplasmic shuttling and nuclear trapping. showing that activation of c-Abl induced by TGF-β is likely to contribute to the fibrosis and vasculopathy of the skin and internal organs in SSc [48] . One additional mechanism involving the c-Abl kinase has been implicated in the development of fibrosis in SSc. This study focused on the activation of Smad1 in SSc and found that that levels of phosphorylated Smad1 were [56] . Furthermore, Akt/PKB may participate in EMT induction through phosphorylation of GSK-3 and also increase cell proliferation and survival through its inhibition of apoptotic pathways. The potential role of PI3K and Akt/PKB in 9 the pathogenesis of tissue fibrosis in SSc has been supported by studies which showed enhanced activation of Akt in SSc fibroblasts [57] and elevated activity of PI3K and Akt/PKB in platelets from patients with SSc [58] . TβR are internalized both by caveolin-1 associated lipid rafts and by early endosome antigen 1 (EEA-1) non-lipid raft pathways. It has been shown, furthermore, that non-lipid raft associated internalization increases TGF-β signaling, whereas, caveolin-associated internalization increases TβR degradation, thereby effectively decreasing or abolishing TGF-β signaling [62] .
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Specifically, it was demonstrated that SARA and Smurf, upstream regulators of either TGF-β signaling or TβR degradation, respectively, were localized in distinct subcellular compartments.
The complex SARA/Smad2/3 which initiates TβR-1 signaling was found to be localized in a non-lipid raft EEA-1 positive compartment, whereas the Smurf/Smad7 complex responsible for initiating proteasome degradation of TβRs was found to be localized in caveolin-1 positive lipid rafts. The localization of the TβRs in the EEA-1 positive compartment was responsible for downstream Smad activation, whereas their localization in caveolae lipid rafts caused recruitment of Smurf/Smad7 with subsequent receptor ubiquitination and rapid receptor degradation and turnover [63, 64] . Numerous studies have supported this role of caveolin-1 in the development of tissue fibrosis [65] [66] [67] [68] . For example, it was shown that caveolin-1 knockdown in vitro markedly increased collagen gene expression in normal human lung fibroblasts and that caveolin-1 was reduced in affected SSc lungs and skin [66] and in lung tissues and fibroblasts from patients with idiopathic pulmonary fibrosis [67, 68] . Increasing caveolin-1 expression markedly improved bleomycin-induced pulmonary fibrosis [67] . Furthermore, restoration of caveolin function employing cell permeable peptides abrogated TGF-β activation of cultured human dermal fibroblasts, and it was suggested that restoration of caveolin function employing the active caveolin-1 scaffolding domain coupled to cell-permeable carrier peptides may represent a novel approach for treatment of fibrotic diseases including SSc [65, 66] .
Roles of TGF-β in SSc-associated tissue fibrosis. Numerous studies have shown that alterations in TGF-β signaling are involved in the pathogenesis of diverse human diseases [69-12 72] . However, owing to its multiple and potent profibrotic effects, TGF-β has been considered one of the key molecules involved in the pathogenesis of a variety of fibrotic diseases as well as in SSc tissue fibrosis [1] [2] [3] [4] [73] [74] [75] [76] [77] . One of the most important effects of TGF-β1 is the stimulation of the synthesis of a variety of ECM macromolecules by fibroblasts and other mesenchymal cells as evidenced by a remarkable increase in response to TGF-β treatment of the production of collagens type I, III, V, and VI, fibronectin and α-smooth muscle actin (α-SMA), a molecular marker of activated myofibroblasts [78] [79] [80] [81] [82] [83] . TGF-β1 also decreases the synthesis of collagen-degrading metalloproteinases and stimulates the production of protease inhibitors such as tissue inhibitor of metalloproteinases 1 (TIMP-1) [84, 85] . Small amounts of TGF-β sensitize fibroblasts to its own effects and maintain them in a persistently activated state involving an autocrine mechanism that causes further production of TGF-β [86] . It has also been shown that SSc fibroblasts express increased numbers of TGF-β receptors on their surface and display altered ratios of these receptors, alterations that have been suggested to account for the increased TGF-β-induced signaling and the resulting stimulation of collagen production in these cells [87] .
Another important profibrotic effect of TGF-β is the induction of epithelial-mesenchymal transition [12] [13] [14] 88, 89] and although less extensively studied, it also appears that TGF-β might induce a similar transdifferentiation process in endothelial cells [22] [23] [24] . Another important effect of TGF-β is the potent downregulation of caveolin-1 expression resulting in a marked reduction of its protein levels. As discussed above and illustrated in The reduction in TGF-β1 correlated with recent onset and more extensive skin sclerosis, suggesting that active TGF-β1 may be sequestered in actively involved SSc skin [90] .
Several studies examined the spontaneous production of active and total (active plus latent) TGF-β1 by cells from SSc patients. One study examined the production of TGF-β from peripheral blood mononuclear cells (PBMC). Greater amounts of both latent and active TGF-β were produced by PBMC from SSc patients than those from normal subjects in autologous mixed lymphocyte reaction assays [91] . Another study showed that PBMC from patients with limited or diffuse cutaneous SSc had significantly elevated values compared to PBMC from normal controls. Furthermore, PBMC from patients with disease of recent onset displayed increased production of active or total TGF-β1 compared to patients with disease of less recent onset. However, although the production of active TGF-β1 by PBMC from patients with diffuse
SSc was higher compared with PBMC form patients with limited SSc, the differences were not statistically significant. Analysis of leukocyte subsets showed that the spontaneous production of total TGF-β1 in SSc patients was significantly higher in cultured peripheral monocytes/macrophages, but not in T cells, B cells, or NK cells [92] . In subsequent studies, the production of active and total TGF-β1 levels by cultured dermal fibroblasts was measured. SSc fibroblasts expressed increased levels of TGF-β type I and type II receptors but the secreted amounts of TGF-β were similar to those secreted by normal fibroblasts [93] . 
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The initial step in activation of the TGF-β signaling pathway involves the release of the active polypeptide from its sequestered precursor bound in a latent state to ECM proteins. One of the novel mechanisms involved in this process was recently shown to require the induction of conformational changes in the protein by αvβ5 integrin [31] . Therefore it was of interest to examine the levels of this integrin in SSc. In one study, levels of αvβ5 expression were found to be significantly elevated in SSc fibroblasts compared with normal fibroblasts, and treatment of these cells with anti-αvβ5 antibody or β5 antisense oligonucleotide significantly blocked the TGF-β pathway causing reduced collagen gene promoter activity and reversal of the myofibroblastic features of SSc fibroblasts. These results indicated that upregulated expression of αvβ5 integrin contributes to the establishment of autocrine TGF-β signaling in SSc fibroblasts through activation of endogenous latent TGF-β1 [94] .
Following release of active TGF-β from its ECM storage sites, a dimeric form of the polypeptide engages the corresponding cellular membrane receptor. Studies of the expression levels of TGF-β receptors in SSc skin biopsies using in situ hybridization and immunohistochemical analysis showed that the expression levels of both TβRI and TβRII were elevated in the dermal fibroblasts of SSc skin sections in comparison to normal skin sections, and the numbers of fibroblasts expressing these TβR were increased in the SSc skin sections compared to normal controls. These results suggested that an autocrine TGF-β signaling due to the overexpression of TβRI and TβRII in dermal fibroblasts is involved in the pathogenesis of dermal fibrosis in patients with SSc [95] .
In fibroblasts, TGF-β signaling occurs primarily through the ALK-5 type I TβR receptor which triggers the canonical Smad signaling pathway. Accordingly, numerous studies have examined these early steps of the TGF-β signaling cascade. In one study, the effects of SB431542, a small-molecule inhibitor of ALK-5, were examined in cultured fibroblasts and it was shown that SB431542 abrogated TGF-β-induced phosphorylation and nuclear transport of endogenous Smad2/3 and Smad4 and it inhibited TGF-β-induced stimulation of collagen, fibronectin, and connective tissue growth factor gene expression. The ALK-5 inhibitor also abolished TGF-β autoinduction and myofibroblast transdifferentiation [96] . In a related study, the effect of the ALK-5 inhibitor SD208 on the expression of key biochemical markers of the 
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To further characterize the mechanism of regulation of collagen gene expression in SSc and healthy skin fibroblasts the roles in TGF-β signaling of the p38 mitogen-activated protein kinase (MAPK) which is an important regulator of stress responses and apoptosis, and of the coactivator histone acetyl transferase p300, which regulates cell differentiation, were examined. In the studies of p38, treatment of dermal fibroblasts with TGF-β resulted in a prolonged activation of this kinase. Furthermore, a specific inhibitor of p38 suppressed TGF-β stimulation of collagen type I mRNA and the α2(I) collagen promoter activity, whereas ectopic expression of p38α enhanced the promoter activity of the collagen gene and potentiated TGF-β stimulation of this promoter. However, both cell types exhibited similar total levels of p38 MAPK and similar kinetics of p38 activation in response to TGF-β suggesting that the p38 MAPK pathway is not dysregulated in SSc fibroblasts [102] . In the studies with p300 it was shown that TGF-β induced an increase in p300 levels in normal fibroblasts and that forced expression of p300 dramatically enhanced the magnitude of TGF-β responses. Furthermore, TGF-β lost its ability to induce Smad-dependent transcription in p300-depleted fibroblasts. These responses could be fully rescued with ectopic p300. Levels of p300 were higher in cultured fibroblasts derived from SSc patients than in fibroblasts from matched normal controls. These results established conclusively that p300 is an essential component of the cellular TGF-β signal transduction pathways mediating stimulation of collagen synthesis in fibroblasts and may, therefore, be an important contributor to the progression of skin fibrosis in SSc and may represent a novel therapeutic target [103] . 
TGF-β microarray
Connective tissue growth factor (CTGF)
. CTGF, also known as CCN2, is another pleotropic growth factor that has recently emerged as an important mediator of normal and pathological tissue fibrotic responses [105] [106] [107] and has been suggested to play a crucial role in SSc tissue fibrosis [108] [109] [110] . CTGF was originally identified in human umbilical vein endothelial cells, and previous studies revealed that human skin fibroblasts produce CTGF following stimulation with TGF-β [105] . In addition to a potent profibrotic effect, CTGF participates in angiogenesis, axial development of the musculoskeletal system, structural organization of connective tissues, and embryo implantation. TGF-β stimulates CTGF synthesis in fibroblasts, vascular smooth muscle cells and endothelial cells, and numerous studies have
shown that it represents a downstream mediator of TGF-β fibrogenic effects. Indeed, the CTGF produced by these cells in response to TGF-β stimulation in turn stimulates the synthesis of such [108] [109] [110] . A study to determine the clinical correlation of CTGF serum levels in patients with SSc showed that SSc patients with elevated CTGF had disease of more recent onset and of greater severity, including the more frequent development of pulmonary fibrosis with decreased DLCO and decreased vital capacity.
Thus, serum CTGF levels were increased in patients with more severe SSc and correlated with the extent of skin sclerosis and the severity of pulmonary fibrosis [111] . Another study assessed CTGF expression in SSc tissues and found strong CTGF signals in fibroblasts of affected skin from patients with SSc, whereas there was no expression in the skin from normal controls [112] .
CTGF has also been found to be overexpressed in lung fibroblasts isolated from SSc patients. A recent study examined CTGF induced changes in the lung fibroblast proteome and identified novel CTGF-responsive molecules that may play important roles in pulmonary fibrosis. One of these novel CTGF-induced proteins, IQ motif containing GTPase activating protein (IQGAP) 1, was found to be elevated in lung fibroblasts isolated from SSc patients with pulmonary fibrosis.
Depletion of IQGAP1 expression by small interfering RNA inhibited CTGF-induced cellular migration. These findings further implicate the importance of CTGF in lung tissue repair and fibrosis [113] . [114] . PDGF effects are mediated by a complex cascade initiated by activation of two distinct receptor tyrosine kinases (PDGFRα and β) that drive a potent mitogenic stimulation of vascular smooth muscle cells and dermal fibroblasts [115] . Dysregulation of PDGF signaling has been linked to numerous disorders including atherosclerosis and pulmonary hypertension [116, 117] . PDGF has also been implicated in the pathogenesis of numerous fibroproliferative diseases, including SSc [118] [119] . Elevated expression of PDGF and its receptors has been found in SSc skin and lung tissues and there is evidence that TGF-β stimulates the expression of PDGFRα in SSc cells and increases their response to PDGF, suggesting that cross-talk between TGF-β and PDGF pathways may regulate chronic fibrosis in SSc [120] .
Platelet-derived growth factor (PDGF)
To examine the role of PDGF and TGF-β in the pathogenesis of SSc-associated pulmonary fibrosis, PDGF and TGF-β levels were determined in bronchoalveolar lavage (BAL)
fluid from patients with SSc and healthy controls. BAL fluid from SSc patients was found to contain significantly elevated levels of PDGF-AA, PDGF-BB, and TGF-β1 [121] . SSc lung myofibroblasts pretreated with TGF-β 1 exhibited an enhanced mitogenic effect upon stimulation by PDGF, caused in part by the induction of the PDGFα receptor. These studies support a role for PDGF and TGF-β 1 in the pathogenesis of SSc lung disease. The potent smooth muscle cell mitogenic effects of PDGF have been implicated in the severe fibroproliferative changes in the pulmonary vasculature occurring during the development of primary pulmonary hypertension [122] and it has been suggested that highly selective tyrosine kinase inhibitors such as imatinib and dasatinib that are capable of abrogating the activation of PDGF receptor tyrosine kinase may be effective therapies for primary pulmonary hypertension and provides support for their use in the treatment of SSc [119, [122] [123] [124] . 
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Of substantial interest has been the recent description of the occurrence in the sera of SSc patients of functional anti-PDGF receptor-specific autoantibodies capable of activating and initiating PDGF signaling [125] . In this study, stimulatory antibodies to the PDGFR that were capable of activating collagen-gene expression and inducing the production of reactive oxygen radicals (ROS) in mouse-embryo fibroblasts were found in all the SSc patients studied. The antibodies recognized native PDGFR, inducing tyrosine phosphorylation and ROS accumulation and stimulation of type I collagen-gene expression as well as myofibroblast phenotype conversion in normal human primary fibroblasts. These results suggested that functional anti-PDGF antibodies have a causal role in the pathogenesis of SSc [126] . Given the potential importance and significance of these results, several subsequent studies were performed to confirm the presence of functional anti-PDGFR antibodies in patients with SSc. In one study, immunoglobulins (IgGs) from 37 patients with SSc were purified and PDGFR activation tested using 4 different bioassays. Purified IgG samples from patients with SSc were positive when tested for antinuclear autoantibodies, but failed to specifically activate PDGFRα or PDGFRβ in any of the tests [127] . Another study employed an electrochemiluminescence binding assay for detection of serum autoantibodies to PDGFRα, PDGFRβ, epidermal growth factor receptor (EGFR), and colony-stimulating factor receptor 1 (CSFR1), and the level of receptor phosphorylation induced by pure Ig was determined by enzyme-linked immunoassay, Western blot, and functional agonist activity mitogenic assay. Although approximately one-third of sera samples from SSc patients contained detectable autoantibodies to PDGFR, these antibodies were not specific to SSc, since they were also detected in a similar percentage of samples from normal subjects. Furthermore, PDGFRα agonist activity was not demonstrated when purified IgG from these sera was tested in cell-based assays [128] . A third study to evaluate the presence of anti-PDGFRα antibodies in patients with SSc found non-significant differences between patients with SSc and controls and there was no correlation between the presence or titers of anti-PDGFRα antibodies and the clinical and serological features of SSc. Furthermore, serum samples from patients with SSc and healthy people recognized the same band corresponding to PDGFRα by immunoblot [129] . Thus, the current evidence is not conclusive and there is substantial controversy and uncertainty about the presence of functional PDGFRα activating antibodies in the sera of SSc patients.
Fibroblast growth factors (FGF).
FGF comprise a large family of growth factors which play a crucial role during embryonic development, participating in numerous differentiation processes including mesoderm induction and mesenchymal-epithelial signaling [130, 131] . FGF are potent mitogenic factors that have numerous functions in adult organisms such as angiogenesis and wound healing [132] . One recent study examined basic FGF (bFGF) expression in skin biopsies from SSc patients and found increased expression in the epidermis and dermis as compared to normal tissues. However, there was no correlation of the levels of expression with the duration of convertdoc.input.557475.l9K2M 9:32:05 PM 22 disease or the extent of skin involvement, although some of the results suggested that bFGF may act in an autocrine or paracrine manner in fibrogenesis [134] . In contrast, another study showed that bFGF is a potent inhibitor of basal and TGF-β stimulated collagen expression in human fibroblasts, and that this effect was no different in SSc than in healthy fibroblasts [135] .
Therefore, the role of FGF in the initiation of progression of the fibrotic process in SSc has not been completely elucidated and additional studies will be required to conclusively determine the contribution of this potent growth factor to the pathogenesis of fibrosis in SSc.
Vascular endothelial growth factor (VEGF).
VEGF is an endothelial cell specific growth factor with multiple functions including stimulation of endothelial cell proliferation and differentiation, modulation of endothelial permeability, and potent effects on vascular remodeling [136] . Expression of VEGF is markedly induced by hypoxia and is regulated by hypoxia-inducible factor 1α. A recent study suggested that tissue hypoxia in affected skin and other organs of patients with SSc may result in alterations in VEGF regulation and therefore may play an important role in the altered angiogenesis which is a characteristic feature in SSc [137] .
Measurement of serum levels of VEGF in patients with SSc and healthy controls showed that serum VEGF levels were significantly higher in SSc patients and correlated well with the extent of skin sclerosis. Serum VEGF levels were also inversely correlated with nailfold capillary density, suggesting that high VEGF levels may participate in the capillary damage in SSc [138] . In another study, serum levels of VEGF were measured in patients with various connective tissue diseases. Patients with diffuse SSc showed elevated VEGF levels in comparison with normal controls. An elevated serum VEGF level was correlated with the frequency of lung fibrosis and reduced vital capacity in the patients with SSc [139] . However, although serum VEGF levels were found to be consistently elevated in SSc patients, the source may play an important role in the altered angiogenesis associated with the disease through the secretion of high levels of VEGF [140] . Given the potent proangiogenic effects of VEGF, the role of this growth factor in the pathogenesis of SSc associated fibroproliferative alterations such as pulmonary artery hypertension (PAH) has been the subject of intense investigation. An evaluation of the relationships between pulmonary artery pressure, clinical and functional manifestations of SSc and serum VEGF levels showed that serum VEGF levels were increased in SSc patients with PAH and suggested a possible role of VEGF in the pathogenesis of PAH in SSc [141] .
It has been proposed that the disturbed vessel morphology with enlarged capillaries and an overall reduction in capillary density frequently present in SSc may represent an insufficient angiogenic response and that these abnormalities may be due to reduced VEGF expression.
However, in refutation of this hypothesis was the observation that the expression of both VEGF and its receptors VEGFR-1 and VEGFR-2 were upregulated in SSc skin. Upregulation of VEGF was likely mediated by an altered expression pattern of various cytokines [142] . Thus, these results do not support the notion that alterations in VEGF signaling are responsible for the occurrence of capillary abnormalities in SSc.
Insulin-like growth factor (IGF) and insulin-like growth factor binding proteins (IGFBP).
IGFs comprise a family of regulatory polypeptides with high sequence similarity to insulin that are involved in numerous physiologic states including growth and development, cellular proliferation and apoptosis, and aging [143, 144] . IGFs are part of a complex protein [146] .
Supporting the profibrotic role of IGFBP, elevated levels of IGFBP-3 and -5 were found in pulmonary fibrosis [147] . Furthermore, measurements of serum IGF-1 and IGFBP-3 levels in patients with SSc were found to be significantly elevated compared with patients with systemic lupus erythematosus or healthy controls. IGF-1 levels correlated with the extent of skin involvement and the presence of pulmonary fibrosis. Furthermore, IGF-1 mRNA was upregulated in the affected skin of patients with SSc. These results collectively suggested that IGF-1 and IGFBP-3 are involved in the development of fibrosis in SSc [148] .
In another study, IGF-2 expression was examined in explanted lung tissues from control and SSc patients to determine its role in the pathogenesis of SSc associated pulmonary fibrosis.
Immunostaining revealed increased IGF-2 expression in fibroblastic foci of SSc lungs and cultured primary SSc lung fibroblasts had a fourfold increase in IGF-2 mRNA and a twofold increase in IGF-2 protein compared with normal lung fibroblasts. IGF-2 induced a dose-and time-dependent increase in collagen type I and fibronectin production and triggered the activation of several important kinase pathways including the PI3K signaling cascade. These results provided strong support and novel insights into the role of IGF-2 in the pathogenesis of SSc-associated pulmonary fibrosis [149] . 
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Concluding Remarks
Remarkable recent progress in the understanding of the molecular events involved in the development of SSc tissue fibrosis has allowed the identification of key molecules, key cellular mechanisms, and key intracellular signaling cascades that mediate the initiation and progression of fibrosis in this disorder. Results of these studies have provided novel approaches for the treatment and correction of the molecular alterations involved in the fibrotic component of SSc, among which the most promising appear to include modifiers of TGF-β1 activation and signaling, tyrosine kinase inhibitors, and inhibitors of other growth factors involved in the fibrotic process [48, 51, 150] . Many of these approaches have already been confirmed by extensive clinical and preclinical evidence and it is likely that they will be available for clinical use in the near future. Furthermore, it is expected that given the strong molecular rationale for their use these novel therapies will be highly effective in controlling and reversing the severe clinical manifestations of the fibrotic process in SSc. 
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